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Summary
When studied in receiving trials at three
locations, health or performance of calves
receiving a core antigen vaccine was not im-
proved.
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Performance.)
Introduction
Undifferentiated bovine respiratory disease
results in millions of dollar s lost each year to the
beef cattle industry.  The cause is often multi-
factorial but may involve viral or  bacterial
agents, or both, in addition to risk factors that
increase susceptibility to the disease.  Gram
negative bacteria such as Pasteurella
hemolytica and P. multocida are often involved.
Disease conditions caused by gram negative
bacteria are most often consequences of the
animal's reaction to a lipopolysaccharide
component  of bacterial cell walls called endo-
toxin.  Effects of endotoxin include increased
heart rate with decreased cardiac output, de-
creased systemic blood pressure, and hyper-
thermia followed by hypothermia, respiratory
distress, and diarrhea.
Numerous commercial vaccines have been
developed to prevent respiratory disease, but the
success of vaccination with some of these
products has been debatable.  Recent develop-
ments have made it possible  to prepare vaccines
from isolated bacterial cell wall components
called core antigens.  Limited information is
available on the efficacy of these products in
reducing the effects of gr am negative infections,
particularly respiratory disease.  These trials
were designed to evaluat e the efficacy of E. coli
J5 core antigen vaccine on health and perfor-
mance of beef cattle under the difficult condi-
tions surrounding their arrival at feedlots that
result in respiratory disease.
Experimental Procedures
Approximately   115-200 calves at each of
three different sites were used in the study.
Each site represented a different set of risk
factors for respiratory disease.  Trial 1 repre-
sented long haul, moderately to highly stressed
calves weighing approximately 500-550
pounds. Trial 2 represented freshly weaned,
short haul, moderately stressed calves weighing
approximately 516 pounds.  Trial 3 represented
long haul, highly stressed bull calves weighing
approximately 550 pounds.
Trial 1.  This trial was a completely ran-
domized design with a four-way treatment
structure.  Treatment 1 was tilmicosin
(Micotil® 8cc) given subcutaneously as a mass
medication on arrival, plus the E. coli core
antigen vaccine.  Treatment 2 was 20 cc of 100
mg oxytetracycline given intramuscularly as a
mass medication on arrival, plus core antigen
vaccine.  Treatments 3 and 4 were tilmicosin or
oxytetracycline  without the core antigen vac-
cine.  All calves received IBR, PI3, BVD,
BRSV (MLV), and a clostridial 7-way vaccine
and were dewormed on arrival.  Calves  were
purchased in Mississippi, processed on the day
of arrival, and  randomly assigned to one of the
four treatments.
Trial 2.  This trial was a completely ran-
domized design with calves randomly assigned
to one of two treatments and one of four pens.
 Calves were removed from the cows, held off
feed and water overnight and processed the
following morning.  Treatment 1 received the E.
coli core antigen vaccine, and treatment 2 did
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not.  All calves were given IBR, PI3, BVD,
BRSV (MLV), and 7-way clostridial vaccines
and were dewormed at processing.
Trial 3.  This trial was a completely ran-
domized design, with calves assigned to one of
two treatments across pens.  One hundred
fifteen bull calves weighing approximately 550
pounds were purchased from Missouri.  Calves
were processed approximately 2 1/2 days after
arrival and subsequently monitored for signs of
illness.  Treatment 1 received E. coli core
antigen vaccine on arrival; treatment 2 calves
did not.  All calves received IBR, PI3, BVD,
BRSV (MLV), and 7-way clostridial vaccine
and were dewormed on arrival.
Results and Discussion
Trial 1.  One hundred ninety five calves
were included in this study.  Thirty five were
diagnosed with respiratory disease, for a mor-
bidity rate of 17.9%.  Data are shown in Table
1.  Peak incidence of mor bidity occurred on day
5.  No calves died.
There was a significant treatment effect in
the number of pulls.  The comparison favored
the cattle that were mass medicated on arrival
with tilmicosin (P=.0074), regardless of the
effect due to the core antigen vaccine.  Micotil®
is a long acting, macro-
lide antibiotic, that has been proven to reduce
morbidity when used as a mass medication on
arrival.  Growth performance data was not
collected at this site.
Trial 2.  Peak incidence of morbidity oc-
curred approximately day 9 post weaning.  A
total of 107 calves were diagnosed as ill out of
243, and one calf died of bloat.  Data are shown
in Table 2.  There were no significant differ-
ences in morbidity due to treatment.
Trial 3.  A total of 94 calves out of the 115
were diagnosed and pulled for respiratory
disease.  Peak incidence of morbidity occurred
on day 10.  Results are shown in Table 3.  No
significant differences occurred in the number
of pulls or deaths for those calves receiving or
not receiving the core antigen vaccine.
No differences occurred in growth per-
formance of calves in the first 21 days of the
receiving phase.
The use of respiratory vaccines to prevent
undifferentiated  bovine respiratory disease is a
well accepted practice in the beef industry.
There is recent interest in the use of core anti-
gen vaccines to prevent the effects of
endotoxemia,  which accompanies gram nega-
tive respiratory infections.  Our work indicates
that, in several different stress categories and
types of cattle, there is no benefit to the use of
Escherichia coli core antigen vaccine against
undifferentiated bovine respiratory disease.
Table 1. Effect of a Core Antigen Vaccine on Morbidity of Moderate-
ly Stressed Long-Haul Calves
Treatment
No. of
Pullsa % Morbid.
No. of
Calves
tilmicosin + core antigen  4  8.2 49
oxytetracycline + core Antigen  11 22.4 49
tilmicosin  6 12.5 48
oxytetracycline 14 28.6 49
Removal from pens for treatment of respiratory disease.a
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Table 2. Effect of a Core Antigen Vaccine on Morbidity and Growth Performance of
Moderately-Stressed, Weaned Calves
Treatment
No. of
Pullsa % Morbid.
ADG 
(30 Days)
No. of Calves
Core antigen 52 48.6 1.70 121
No antigen 55 51.4 1.58 122
Removal from pens for treatment of respiratory disease.a
Table 3. Effect of a Core Antigen Vaccine on Morbidity, Mortality and Growth
Performance of Highly Stressed Bull Calves
Treatment
No. of
Pulls /Deathsa
Percent
Morbid./Mort.
Mean ADG
(21 days)
No. of
Calves
Core antigen 49/3 87.5/5.4 0.6 56
No antigen 45/5 76.3/8.5 0 59
Removal from pens for treatment of respiratory disease.a
